The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Growing Number of Countries Adopting Flexible Intellectual Property Regulations After India Issues Country's First Compulsory License

June 22, 2012

"A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health," India's Economic Times reports, noting, "In March, India issued the country's first compulsory license, allowing [Natco Pharma] to legally manufacture and sell a low-cost version of German drugmaker Bayer AG's patented cancer drug, Nexavar, at 3 percent of the original medicine's price on the grounds that Bayer's drug was not meeting public health requirement." The news service writes, "Although multinational companies have criticized India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina, and the Philippines are adopting similar provisions."

China last month "amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs," the news service writes, adding, "According to DG Shah, secretary-general of the Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India's decision to grant compulsory license to Natco Pharma." The news service continues, "Multinational companies [MNCs] as well as some countries, including the U.S., have been critical about India's implementation of IP laws and the liberal use of the compulsory license provision," noting, "India and China, which together account for about a third of the world's population, form a critical market for MNCs" (Singh, 6/22).

Back to other news for June 2012

This information was reprinted from with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
See Also
More on Generic/Discount HIV Drug Access in the Developing World

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: